This is why we are in the best position we’ve ever been in, we have deal people in place and we have a drug Big Pharma wants. One talk with Sidley I’m sure would mean Amarex would be viewed as an asset and not a liability and one a that could be dealt with on the side. If a deal happens sooner our product becomes an asset for trials before expiring. Lots of deal pluses, can’t think of much in the minus column. Will happen and more than likely soon. Trials for cancer could start in Brazil immediately for cancer, LH etc.